An engineered oncolytic parapoxvirus induces immunogenic tumor cell death and displays antitumor efficacy by enhancing T cell responses.

Qi Li Jing Lin Fei Gao Xinyue Wang Yingji Ma Chengyi Zhang Haizhu Wu Fanglin Zhao Ying-Hao Song Mengshi Xu Wenqi He Kui Zhao Guowen Liu Jiyu Guan

Aug 2026 · Biochemical Pharmacology · Vol 253, pp. 118339 · 0 citations

Medicine

TL;DR

These findings establish ORFVΔ-IL15 as a novel therapeutic agent that integrates oncolytic and immunoregulatory functions, demonstrating robust tumor-suppressive efficacy and offering a promising strategy for next-generation oncolytic virus engineering.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Aug 2026

Immune responses elicited by rMV-SLAMblind oncolytic therapy exert a synergistic effect on cancer therapy

Oncolytic virotherapy has emerged as a promising strategy for cancer therapy. rMV-SLAMblind is a recombinant measles virus that lacks the ability to interact with SLAM and specifically infects and lyses NECTIN4 + cancer cells. We previously reported that rMV-SLAMblind oncolytic virotherapy (rMV-OVT) exerts anti-t...

Kanako Moritoh, Tomoko Fujiyuki, Y. Amagai et al. · Scientific Reports · 0 citations

Sep 2026

Immunodominant Antiviral T Cell Responses Outcompete Antitumor T Cell Responses to Reduce the Efficacy of Oncolytic Viroimmunotherapy.

The paradigm in the field of oncolytic virotherapy proposes that tumor cell killing by an oncolytic virus (OV) culminates in the priming of antitumor CD8+ T cells. However, this ignores the impact a highly immunodominant antiviral response against the OV has on the subdominant antitumor response, particularly regarding...

Benjamin L. Kendall, O. Liseth, T. Sangsuwannukul et al. · Cancer Research · 0 citations

Review Open access Sep 2026

Oncolytic virotherapy at the tumor microenvironment-CAR Therapy interface: Mechanisms, clinical translation, and future directions.

Oncolytic virotherapy has evolved from a tumor-selective cytolytic strategy into a programmable immunotherapeutic platform that reshapes the tumor microenvironment (TME). Oncolytic viruses (OVs) selectively infect malignant cells, induce immunogenic cell death, release tumor antigens, and activate innate and adaptive i...

A. Atoom, J. Rizaev, D. Polatova et al. · Cancer Treatment and Researc... · 0 citations

Open access Sep 2026

Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages

Immunosuppressive tumor-associated macrophages (TAMs) create a barrier to effective antitumor immunity and promote therapeutic resistance. Reeducating TAMs to enhance their antitumor capabilities through phenotypic remodeling remains challenging. Here, we report a modular oncolytic herpesvirus platform, engineered with...

Chao-Long Lin, Shao-Peng Li, R. Lou et al. · Science Advances · 0 citations

Sep 2026

An oncolytic virus armed with fowl adenovirus fiber-modified recombinant TRAIL enhances tumor targeting and immunotherapy activity.

Oncolytic viruses have emerged as a promising strategy in cancer immunotherapy and have been applied to the treatment of various tumors. We previously demonstrated that oncolytic adenoviruses engineered expressing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) could induce apoptosis in tumor cells and...

Wen-Mo Liu, Li-Ying Wang, Xu-Pu Wang et al. · Molecular Cancer Therapeutic... · 0 citations

Open access Sep 2026

Intravenously deliverable oncolytic virus VET3-TGI favorably alters the tumor microenvironment

Abstract Background Oncolytic viruses have pledged to combat cancer by causing immunogenic cell death of cancerous cells while priming cancer-specific immune responses. These outcomes have proven elusive in the clinic. Current-generation vectors rarely reach effective concentrations inside tumors when given intravenous...

Ming Zhang, Katy Barrett, Carly J. Carter et al. · Journal for ImmunoTherapy of... · 0 citations